SCHEDULE: Jeffrey Sharpe Boosts Conexeu Sciences Stake to 5.4%

Jeffrey Sharpe has increased his beneficial ownership in Conexeu Sciences Inc. to 5.4% following the vesting of performance warrants tied to market capitalization milestones.

Summary

• Jeffrey Sharpe, a director of Conexeu Sciences Inc., has increased his beneficial ownership to 5.4% of the company's common stock.
• This increase is due to the vesting of 500,000 performance warrants on June 18, 2026, which were contingent on the company's stock trading at a market capitalization of $80 million or greater for 20 consecutive days.
• Sharpe now directly holds 1,000,000 shares and has exercisable warrants for an additional 500,000 shares, totaling 1,500,000 shares.
• An additional 500,000 performance warrants remain unvested, contingent on the submission of a 510(k) application to the FDA.
• The total shares outstanding as of August 17, 2026, are reported as 27,397,164.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the reporting person's increased beneficial ownership and the achievement of key milestones, indicating progress for Conexeu Sciences Inc.

Positives

• Achievement of a significant market capitalization milestone ($80 million for 20 consecutive trading days) leading to warrant vesting.
• Increased beneficial ownership by a key insider (Director Jeffrey Sharpe) to 5.4%, indicating confidence or alignment with company progress.
• Successful exercise of vested warrants for 500,000 shares at a nominal cost of $0.001 per share.
• The company has successfully listed on the Nasdaq Stock Market.
• Milestone 1 (collagen study results) was achieved on July 8, 2025.

Negatives

• 500,000 performance warrants remain unvested, contingent on a future FDA 510(k) application submission, introducing uncertainty.
• The exercise price for some warrants was $0.001 per share, indicating a very low initial valuation or compensation structure.

Risks

• The vesting of 500,000 performance warrants is contingent on the submission of a 510(k) application to the U.S. Food and Drug Administration, which may face delays or rejection.
• Future acquisition or disposition of securities by the Reporting Person is subject to market conditions and other factors, introducing potential for share price volatility.
• The Reporting Person reserves the right to formulate other plans or proposals, which could impact the company's strategic direction or shareholder value.

Future Outlook

The filing indicates that 500,000 performance warrants remain unvested, contingent upon the submission of a 510(k) application to the U.S. Food and Drug Administration. The reporting person, Jeffrey Sharpe, reserves the right to acquire or dispose of securities based on market conditions and may formulate other plans or proposals regarding his interest in the Issuer.

Management Comments

• The Reporting Person currently holds the shares of Common Stock and the Performance Warrants for investment purposes.
• The Reporting Person reserves the right to formulate other plans or make other proposals and take other actions with respect to his interest in the Issuer.
• Depending on market conditions and other factors, the Reporting Person may acquire or dispose of securities of the Issuer as the Reporting Person may deem appropriate, whether in open market purchases or sales, privately negotiated transactions or otherwise.
• The Reporting Person continues to evaluate numerous potential transactions and in connection therewith may exchange shares of Common Stock for other assets or may sell shares of Common Stock to increase his cash position.
• The Reporting Person may also reconsider and change his plans or proposals relating to the foregoing.

Industry Context

StockSavvy.ai notes that this filing reflects typical insider activity following significant corporate milestones such as a Nasdaq listing and achievement of market capitalization targets. The reliance on FDA 510(k) submission for further warrant vesting highlights the company's focus on regulatory approval for its products, a critical path for many biotech and medical device companies.

Related Party Transactions

• Consulting services agreement between Conexeu Sciences Inc. and 1036030 B.C. Ltd. (solely owned by Jeffrey Sharpe) dated May 14, 2025, for which 2,000,000 Performance Warrants were granted.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling confidence. However, potential future sales by the reporting person could impact share price.
• Employees: Vesting of warrants tied to company performance can align management and employee incentives.
• Creditors: No direct impact mentioned.

Next Steps

• Submission of a 510(k) application to the U.S. Food and Drug Administration for the remaining 500,000 performance warrants to vest.
• Reporting Person may acquire or dispose of securities of the Issuer based on market conditions.
• Reporting Person may exchange shares for other assets or sell shares to increase cash position.
• Reporting Person may reconsider and change plans or proposals.

Key Dates

Recommendation

The filing indicates positive progress with milestone achievements and increased insider ownership. However, a significant portion of performance warrants remain unvested, contingent on FDA approval, introducing future uncertainty. The reporting person's stated flexibility to buy or sell shares also adds a layer of unpredictability. Therefore, a 'hold' recommendation is appropriate pending further clarity on the FDA submission and its outcome.

Keywords

Conexeu Sciences, Jeffrey Sharpe, Schedule 13D, Beneficial Ownership, Performance Warrants, Nasdaq Listing, Market Capitalization, FDA 510(k)